Devices › Stimulator, spinal-cord, totally implanted for pain relief
Device brand name · Stimulator spinal-cord totally implanted for pain relief
Restore Rechargeable Neurostimulator: medical device reports filed with FDA
917 reports name it, 2006–2011. Manufacturer given most often on reports: Medtronic Puerto Rico Operations. Product code LGW.
- 917
- device reports naming the brand
- 0% of all MAUDE reports · about 46 a year
- 0
- reports, 12 months to August 2026
- 0 in the 12 months before
- 50.7%
- classified as malfunction
- 27.3% across the product code
- 1.1%
- classified as death, as reported
- 10 reports · not verified by FDA
FDA's MAUDE database holds 917 reports that name the brand "Restore Rechargeable Neurostimulator" (stimulator spinal-cord totally implanted for pain relief), received between October 2006 and October 2011; the manufacturer given most often on reports is Medtronic Puerto Rico Operations. Spellings of one product vary from report to report.
0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (50.7%), injury (48.2%) and death (1.1%); across all stimulator, spinal-cord, totally implanted for pain relief reports (product code LGW) death is recorded in 0.5% and malfunction in 27.3%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are high impedance (15.4%), inappropriate/inadequate shock/stimulation (12.9%) and replace (9.1%). The patient problems coded most often are therapeutic response, decreased, electric shock and inadequate pain relief. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
No report naming Restore Rechargeable Neurostimulator was received in the five years to August 2026; the latest was received in October 2011.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 378,355 reports carrying product code LGW. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| High impedance | 141 | 15.4% | 9.7% |
| Inappropriate/inadequate shock/stimulation | 118 | 12.9% | 3.7% |
| Replace | 83 | 9.1% | 0.4% |
| Device operates differently than expectedthe device behaved unexpectedly | 79 | 8.6% | 7.5% |
| Migration or expulsion of device | 66 | 7.2% | 4.7% |
| Explanted | 62 | 6.8% | 0.8% |
| Failure to charge | 59 | 6.4% | 1.3% |
| Insufficient device problem information | 48 | 5.2% | 6.8% |
| Device remains implanted | 42 | 4.6% | 0.3% |
| Premature discharge of battery | 30 | 3.3% | 1.1% |
| Intermittent continuity | 29 | 3.2% | 1.5% |
| Low battery | 28 | 3.1% | 1.2% |
| Dislodged | 27 | 2.9% | 0.1% |
| Fracturea broken bone | 22 | 2.4% | 1.8% |
| Charging problem | 21 | 2.3% | 11.2% |
| Implant, repositioning of | 19 | 2.1% | 0.2% |
| No telemetry | 19 | 2.1% | 0% |
| Device inoperablethe device could not be used | 17 | 1.9% | 0.7% |
| Impedance problem | 17 | 1.9% | 1.9% |
| Lead(s), breakage of | 16 | 1.7% | 0% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Therapeutic response, decreased | 224 | 24.4% |
| Electric shockan electric shock | 124 | 13.5% |
| Inadequate pain relief | 122 | 13.3% |
| Painpain, site not specified | 108 | 11.8% |
| Surgical procedure, additional | 105 | 11.5% |
| Surgical procedure | 79 | 8.6% |
| Undesired nerve stimulation | 64 | 7% |
| Identified diagnosis | 53 | 5.8% |
| Burning sensationa burning feeling | 34 | 3.7% |
| Discomfortdiscomfort | 24 | 2.6% |
| Therapeutic effects, unexpected | 23 | 2.5% |
| Device overstimulation of tissue | 22 | 2.4% |
| Falla fall | 21 | 2.3% |
| Painful stimulation | 19 | 2.1% |
| Deaththe patient died; cause not stated by this term | 10 | 1.1% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Restore Rechargeable Neurostimulator | Product code LGW | All MAUDE reports |
|---|---|---|---|
| Reports | 917 | 378,355 | 26,136,888 |
| Share of that pool | — | 0.2% | 0% |
| Classified as death, per 1,000 reports | 11 | 5 | 9 |
| Classified as injury | 48.2% | 72% | 36.2% |
| Classified as malfunction | 50.7% | 27.3% | 62.3% |
| Filed by the manufacturer | 100% | 99.5% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code LGW
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Intellis | 42,032 | 4,743 | 0% |
| Octrode Lead Kit, 60cm Length | 47,037 | 5,133 | 0.1% |
| SureScan | 33,123 | 490 | 0% |
| Precision? | 26,020 | 446 | 0.4% |
| Proclaim 5 Elite Implantable Pulse Generator | 20,816 | 2,057 | 0.1% |
| Precision Spectra ? | 16,858 | 971 | 0.5% |
| Restore Ultra | 13,500 | 39 | 0.1% |
| Eon Mini IPG, 16-Channel Rechargeable | 14,176 | 111 | 0.2% |
| Restore Sensor | 10,934 | 40 | 0.1% |
| Spectra WaveWriter? | 7,766 | 1,093 | 0.4% |
| Penta 3mm Lead, 60 cm | 9,617 | 839 | 0.3% |
| Senza | 6,423 | 718 | 15.1% |
| Eon Mini | 9,122 | 0 | 0.6% |
| Proclaim 7 Elite Implantable Pulse Generator | 5,836 | 333 | 0.1% |
| WaveWriter Alpha? | 4,965 | 1,591 | 0.9% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Restore Rechargeable Neurostimulator reports
How many FDA reports name Restore Rechargeable Neurostimulator?
917 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.
What kinds of events are reported?
malfunction (50.7%), injury (48.2%) and death (1.1%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
high impedance (15.4%), inappropriate/inadequate shock/stimulation (12.9%), replace (9.1%), device operates differently than expected (8.6%) and migration or expulsion of device (7.2%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Restore Rechargeable Neurostimulator was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.